Related Experiment Video

Updated: May 9, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

LR11: a novel biomarker identified in follicular lymphoma

Takeharu Kawaguchi1, Chikako Ohwada, Masahiro Takeuchi

  • 1Department of Haematology, Chiba University Hospital, Chiba, Japan.

British Journal of Haematology
|July 16, 2013
PubMed
Abstract

No abstract available in PubMed .

Keywords:
FLIPI-2LR11biomarkerfollicular lymphomaprogression free survival

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: May 9, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Articles linked to this work by shared authors, journal, and citation graph.

Workforce Entry and Employment Trajectories among Adolescent and Young Adult Hematopoietic Cell Transplant Survivors without Prior Employment.

Transplantation and cellular therapy·2026

Epstein-Barr virus-associated chromatin activation and enhancer engagement in T/NK-cell lymphoproliferative diseases.

Blood·2026

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Prolonged engraftment syndrome following autologous stem cell transplantation in Hodgkin lymphoma with prior immune checkpoint inhibitor therapy].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis.

Leukemia & lymphoma·2026

Association between the Pharmacokinetic Parameters of Ganciclovir and Clinical Efficacy and Safety in the Treatment of Cytomegalovirus Infection.

Biological & pharmaceutical bulletin·2026

Optimizing cord blood unit selection to improve survival after single-unit unrelated cord blood transplantation for adult myelodysplastic syndrome.

British journal of haematology·2026

A pro-inflammatory cytokine signature characterises thrombotic antiphospholipid syndrome despite stable anticoagulation.

British journal of haematology·2026

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera.

British journal of haematology·2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

British journal of haematology·2026

Predicted microbiome-associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia.

British journal of haematology·2026

Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft-versus-host disease.

British journal of haematology·2026

Does size matter? Tumor density as a predictor of clinically significant prostate cancer on MRI-targeted transperineal prostate biopsy.

International urology and nephrology·2026

Beyond the Document: A Single-Center Qualitative Study of Survivorship Care Plan Barriers and Opportunities Across Pediatric Oncology Stakeholders.

Pediatric blood & cancer·2026

A high-throughput method to computationally develop candidate adverse outcome pathways in humans: a proof of concept with insecticides and Parkinson Disease.

Toxicological sciences : an official journal of the Society of Toxicology·2026

Endometriosis Pain: Genes linked to Inflammation Distinguish Symptomatic from Asymptomatic Disease.

Molecular human reproduction·2026

Endocrine Biomarker Changes in a Randomised Low-Dose Tamoxifen Trial for Breast Cancer Prevention.

Journal of the National Cancer Institute·2026

Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.

Journal of the National Cancer Institute·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us